Physician profile
Alec M Anders
NPI 1659339539
$38,002.40
in general payments reported to CMS, 2019-2025
38 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $13K · 2021: $13K · 2022: $7,235 · 2023: $1,354 · 2024: $1,319 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,629.05 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28,116.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $3,886.43 | 2019-2020 | |
| Lilly USA, LLC | $1,151.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $660.71 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $647.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $589.64 | 2019-2025 | Tezspire, Breztri, Farxiga |
| Abbott Laboratories | $300.18 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $290.58 | 2019-2025 | Trintellix |
| Abbvie INC. | $274.34 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Glaxosmithkline, LLC. | $199.41 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $162.64 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.74 | 2024-2025 | Relistor, Xifaxan, Trulance |
| Mylan Specialty L.P. | $133.89 | 2022 | |
| Horizon Therapeutics Plc | $133.53 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $121.88 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.